ITEMS IN AFP WITH KEYWORD:
This study found little, if any, additional benefit to repeat BMD screening at four years beyond baseline BMD testing in older men and women. A recent similar study (Gourlay ML, Fine JP, Preisser JS, et al. N Engl J Med. 2012;366(3):225–233) recommended a baseline examination at 65 years of age with...
This practice bulletin from the American College of Obstetricians and Gynecologists (ACOG) reviews diagnosis, evaluation, and treatment options for women with osteoporosis.
In 2007, more than 5.4 million patients in the United States were taking oral bisphosphonates. However, bisphosphonates are under scrutiny because of the risk of bisphosphonate-related osteonecrosis of the jaw.
Prolia is an expensive method of preventing osteoporotic hip fractures, and is associated with significant adverse effects. Safer, less expensive options exist for preventing fracture in high-risk women.
Feb 1, 2012 Issue
Human Parathyroid Hormone for Treating Osteoporosis [FPIN's Clinical Inquiries]
Human parathyroid hormone should be used in patients with severe osteoporosis to decrease the rate of vertebral and nonvertebral fractures.
May 15, 2011 Issue
Screening for Osteoporosis: Recommendation Statement [U.S. Preventive Services Task Force]
The U.S. Preventive Services Task Force (USPSTF) recommends screening for osteoporosis in women 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman with no additional risk factors.
Case study: A 59-year-old black woman presents for a routine well visit. She reports that her 60th birthday is in a few days, and asks if she should make an appointment to be screened for osteoporosis. She also asks whether her husband, who is 66 years of age, should be screened as well.
Oct 1, 2010 Issue
Monitoring Osteoporosis Treatment: DXA Should Not Be Routinely Repeated [Editorials: Controversies in Family Medicine]
Unless the physician knows how to adjust therapy based on repeat DXA, monitoring osteoporosis treatment via DXA is unlikely to be clinically necessary or beneficial. Currently, we assume that if the patient has not had a fracture and the BMD significantly increases, then no change in treatment is ne...
Oct 1, 2010 Issue
Bone Density Testing to Monitor Osteoporosis Therapy in Clinical Practice [Editorials: Controversies in Family Medicine]
The bottom line in caring for patients with osteoporosis is that monitoring for treatment effect is appropriate and desirable. A statistically significant BMD loss may lead to further evaluation and possibly a change in treatment. The strategy of monitoring therapy with BMD testing is supported by t...
Osteoporosis is an important and often overlooked problem in men. Although the lifetime risk of hip fracture is lower in men than in women, men are twice as likely to die after a hip fracture. Bone mineral density measurement with a T-score of -2.5 or less indicates osteoporosis. The American Colleg...